financetom
RAPT
financetom
/
Healthcare
/
RAPT
All stocks News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Commodities
RAPT Therapeutics, Inc.RAPT
USD
- At close
USD
- Until the end
The complete list of US stocks
1D
5D
1M
1Y
5Y
MAX
Overview >
% Change
Description >

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States.

Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.

The company's lead oncology drug candidate is FLX475, an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer.

It also focuses on the development of hematopoietic progenitor kinase 1 inhibitor. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019.

RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Latest News >
Sector Update: Financial
Sector Update: Financial
Aug 19, 2024
08:59 AM EDT, 08/19/2024 (MT Newswires) -- Financial stocks were edging higher pre-bell Monday with the Financial Select Sector SPDR Fund (XLF) up 0.1% recently. B. Riley Financial ( RILY ) shares were down more than 8% after saying its Chair and Co-Chief Executive Bryant Riley has made an unsolicited proposal to take the company private for $7 per share....
Sector Update: Tech
Sector Update: Tech
Aug 19, 2024
08:47 AM EDT, 08/19/2024 (MT Newswires) -- Technology stocks were steady premarket Monday, with the SPDR S&P Semiconductor ETF (XSD) inactive and the Technology Select Sector SPDR Fund (XLK) was slightly higher recently. Advanced Micro Devices ( AMD ) shares were up more than 2% after saying it has agreed to acquire artificial intelligence infrastructure provider ZT Systems in a...
Schlumberger, Palo Alto Networks Expand Partnership to Enhance Cybersecurity for Energy Industry
Schlumberger, Palo Alto Networks Expand Partnership to Enhance Cybersecurity for Energy Industry
Aug 19, 2024
08:59 AM EDT, 08/19/2024 (MT Newswires) -- Schlumberger ( SLB ) and Palo Alto Networks ( PANW ) are expanding their partnership to enhance cybersecurity for the energy industry, the companies said Monday. Under the terms, the firms will integrate Schlumberger's ( SLB ) domain, cloud, and edge technologies in the energy sector with Palo Alto's platform-based cybersecurity services, the...
Alzamend Neuro Enters Partnership for Phase II Clinical Trial of Potential Lithium Therapeutic Drug for Post-Traumatic Stress Disorder; Shares Soar
Alzamend Neuro Enters Partnership for Phase II Clinical Trial of Potential Lithium Therapeutic Drug for Post-Traumatic Stress Disorder; Shares Soar
Aug 19, 2024
08:59 AM EDT, 08/19/2024 (MT Newswires) -- Alzamend Neuro ( ALZN ) said Monday it is teaming up with Massachusetts General Hospital for a phase II clinical trial of its lithium therapeutic drug candidate for post-traumatic stress disorder. The study of AL001 aims to compare the increase in lithium levels within the brain and its structures versus a commonly marketed...
Copyright 2023-2025 - www.financetom.com All Rights Reserved